General Information of Drug (ID: DMIKH67)

Drug Name
Valetizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMIKH67

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-339658 DMJ9RN8 Inflammatory bowel disease DD72 Phase 2 [3]
Vatelizumab DM3V7QO Multiple sclerosis 8A40 Phase 2 [2]
Evatak DMNMEAW Solid tumour/cancer 2A00-2F9Z Investigative [3]
TCI15 DM06DI1 Discovery agent N.A. Investigative [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-2/beta-1 (ITGA2/B1) TTMSB0A ITA2_HUMAN-ITB1_HUMAN Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022066)
2 Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2578).
4 Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):719-24.